Q2 FY2026 EarningsQ2 FY26 results slightly exceeded consensus on the top line but missed on bottom-line metrics due to acquisition-related headwinds. Revenue of $6,265M beat the $6,171M mean estimate by 1.53%, supported by a 5.5% YoY growth. However, GAAP EPS of $1.23 missed the $1.285 mean estimate by -4.28%, primarily impacted by nonrecurring costs related to the $9.8B Masimo acquisition. Diagnostics revenue saw a 7.0% boost from the Masimo integration, helping offset a -1.0% decline in core sales caused by lower respiratory testing demand.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Danaher(DHR) the Revenue is 6.265 B (+5.54%), Beat estimate;the EBIT is 1.698 B (+4.94%), Beat estimate;the EPS is 1.23 (+59.74%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
6.26B5.54%
6.17B3.95%
+0.09B1.59%
EBITExceed expectations
1.70B4.94%
1.64B1.52%
+0.06B3.42%
EPSMiss expectations
1.2359.74%
1.306769.70%
-0.07679.96%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf